Latest Production News

Optiscan Imaging has lodged a US FDA 510(k) application for InVue, its precision surgery device designed to provide cellular-level imaging during operations. The submission moves the technology into formal regulatory review, but clearance and commercialisation remain uncertain.

Voltaic Strategic Resources has agreed to acquire five granted Western Australian exploration licences across three gold projects for A$330,000 upfront, with up to A$2 million tied to future Rocky Ridge resource milestones. The deal broadens the explorer’s gold pipeline, but the assets remain at the target-generation stage rather than being defined resources.

PDI Gold has paired a strong September quarter with high-grade drilling beneath its Kiniéro pits, strengthening the case for further resource growth at Guinea’s producing gold operation. The results remain exploration-stage, but the company is preparing a 140,000-metre campaign for 2027.

Osmond Resources has secured the maximum €250,000 provisional grant in the first round of Spain’s national mineral exploration program, while preparing to start a 13-hole campaign at its Orión project. The company has also issued 85 million shares to retain its 80% interest in the project-owning vehicle.

Radiopharm says the FDA has provided a clear framework for the pivotal development of RAD101, its investigational brain metastases imaging agent. The company is preparing for Phase 3 while awaiting formal meeting minutes that could still refine the trial design and regulatory requirements.

Aurora Labs has appointed Andrew Garth as chief executive, moving former CEO Rebekah Letheby into a newly focused chief operating role. The reshuffle is intended to separate commercial strategy from technical execution as the company pursues scaled manufacturing and defence opportunities.

FlexiRoam has onboarded one of Australia’s four major banks to offer complimentary global data roaming on premium rewards Mastercard cards. The live program is expected to generate about USD 140,000 a year under management’s current planning case, although there is no minimum revenue commitment.

AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.

Capricorn Metals produced 31,218 ounces of gold in the September quarter, while its Karlawinda expansion was completed on schedule and within budget. The enlarged operation is now running at 6.5 million tonnes a year, although the next test is converting that capacity into consistent production and costs.

First Graphene has signed a three-year agreement with Turkish manufacturer Aeropreg to develop and potentially commercialise PureGRAPH-enhanced carbon fibre prepreg. The partnership offers a clearer route into aerospace, defence and automotive supply chains, but commercial launch remains dependent on trial results.

Brazilian Critical Minerals has signed binding agreements to acquire 90% of a Brazilian magnesium sulphate producer, aiming to secure a key input for its Ema rare earth project. The strategy offers greater supply-chain control, but the plant requires restructuring and carries estimated legacy liabilities of R$15.3 million.

Buru Energy has formally referred its 100%-owned Rafael Conventional Gas Project to Western Australia’s environmental regulator, with a decision on whether the project requires assessment expected by late 2026. The referral keeps the company’s targets of a final investment decision in the second half of 2027 and first gas in early 2029 in view, subject to approvals.